Results 181 to 190 of about 16,120 (219)
Some of the next articles are maybe not open access.
Tafamidis for transthyretin amyloidosis
Drugs of Today, 2012Tafamidis meglumine (Vyndaqel®, Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairment that is ultimately fatal.
openaire +2 more sources
An aggressive form of transthyretin amyloidosis
Amyloid, 2017In 1990, Ueno et al. identified a new transthyretin (TTR) mutation in a 45-year-old Japanese man with peripheral neuropathy of six-years duration [1].
Noel R, Dasgupta +3 more
openaire +2 more sources
Pathogenesis of transthyretin amyloidosis
Amyloid, 2012Current dogma for transthyretin (TTR) pathogenesis is that mutations in TTR alter its structure such that the tetramer becomes unstable and prone to release of monomer which then becomes the putative building block of the fibril. This hypothesis is supported by thermodynamic data showing decreased stability of mutant TTR tetrameric proteins and ...
openaire +2 more sources
Nephron, 2022
Transthyretin (TTR) amyloidosis (ATTR) is either an inherited condition or a non hereditary disease due to misfolding of wild-type (WT) TTR. Amyloid deposits can be mainly detected in nerves in the inherited form and in myocardium in the acquired variant.
Roberta Fenoglio +7 more
openaire +2 more sources
Transthyretin (TTR) amyloidosis (ATTR) is either an inherited condition or a non hereditary disease due to misfolding of wild-type (WT) TTR. Amyloid deposits can be mainly detected in nerves in the inherited form and in myocardium in the acquired variant.
Roberta Fenoglio +7 more
openaire +2 more sources
Hereditary transthyretin-related amyloidosis
Acta Neurologica Scandinavica, 2018Hereditary transthyretin(TTR)-related amyloidosis (ATTRm amyloidosis) is an endemic/non-endemic, autosomal-dominant, early- and late-onset, rare, progressive disorder, predominantly manifesting as length-dependent, small fiber dominant, axonal polyneuropathy and frequently associated with cardiac disorders and other multisystem diseases.
Josef Finsterer +5 more
openaire +2 more sources
Expanding the spectrum of transthyretin amyloidosis
Muscle & Nerve, 2019See article on pages 95–100 in this issue.
Haruki Koike, Masahisa Katsuno
openaire +2 more sources
Laboratory Assessment of Transthyretin Amyloidosis
Clinical Chemistry and Laboratory Medicine, 2002Mutations in transthyretin (TTR) are the most common cause of autosomal dominant systemic amyloidosis. To date, more than 80 TTR mutations have been associated with amyloidosis in humans. A high prevalence of some mutations like Val122Ile which is identified in 3% of African Americans indicates the necessity of thorough investigation of patients ...
Merrill D, Benson +2 more
openaire +2 more sources
Clusterin regulates transthyretin amyloidosis
Biochemical and Biophysical Research Communications, 2009Transthyretin (TTR) is a human disease-associated amyloidogenic protein that has been implicated in senile systemic amyloidosis (SSA) and familial amyloidotic polyneuropathy (FAP). FAP typically results in severe and early-onset disease, and the only therapy established so far is liver transplantation; thus, developing new strategies for treating FAP ...
Ko-Woon, Lee +9 more
openaire +2 more sources
Rate of Progression of Transthyretin Amyloidosis
The American Journal of Cardiology, 2011Hereditary transthyretin (TTR) amyloidosis is an adult-onset disease characterized mainly by peripheral neuropathy and cardiomyopathy. Although disease progression is usually 5 to 15 years from time of diagnosis to death, no specific measurements of disease progression have been identified.
Merrill D, Benson +5 more
openaire +2 more sources
Vutrisiran for Transthyretin Amyloidosis Cardiomyopathy
Current Vascular PharmacologyAngelica Lehker, Debabrata Mukherjee
openaire +2 more sources